Notícias e Atividades da Kyverna Therapeutics

Kyverna Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Veja o organograma con seus 34 executivos principais

Biografias mais buscadas da Kyverna Therapeutics

• Warner Biddle, Chief Executive Officer and Director
• Mert Aktar, Director
• Sravan Emany, Director

Recentes movimentos de executivos em Kyverna Therapeutics

• Dominic Borie, Strategic Advisor, deixou a Companhia  (Notícia publicada em 15 de julho de 2026).
• Nancy Boman, Chief Regulatory Officer, deixará a Companhia em 3 de ago. de 2026  (Notícia publicada em 10 de julho de 2026).
• Ritesh Srivastava, ingressou na Companhia como Chief Legal and Compliance Officer  (Notícia publicada em 22 de junho de 2026).

Clique aqui para ver outras movimentos em Kyverna Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Kyverna Therapeutics.

Kyverna Therapeutics possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Kyverna Therapeutics

• News Releases | Kyverna Therapeutics
• Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy | Kyverna Therapeutics
• Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Kyverna Therapeutics
• Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Announces First Publication of Ingenui-T, a Novel CAR T-Cell Vein-to-Vein Manufacturing Process | Kyverna Therapeutics
• Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis | Kyverna Therapeutics
• Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases | Kyverna Therapeutics
• View more press releases Close

Redes sociais sobre Kyverna Therapeutics

• Kyverna Therapeutics na Wikipedia, Google News e Yahoo Finance
• Kyverna Therapeutics na LinkedIn, X (Twitter) e YouTube